Equities

Hansoh Pharmaceutical Group Company Ltd

Hansoh Pharmaceutical Group Company Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)18.26
  • Today's Change0.40 / 2.24%
  • Shares traded16.13m
  • 1 Year change+24.90%
  • Beta0.7835
Data delayed at least 15 minutes, as of Nov 21 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments24,85721,62318,933
Total Receivables, Net3,3213,6743,782
Total Inventory576448410
Prepaid expenses1037946
Other current assets, total277.148.46
Total current assets28,88325,83223,179
Property, plant & equipment, net3,2943,4833,569
Goodwill, net------
Intangibles, net1773317
Long term investments685654395
Note receivable - long term------
Other long term assets------
Total assets33,03930,00227,160
LIABILITIES
Accounts payable164222248
Accrued expenses1,9691,9252,201
Notes payable/short-term debt000
Current portion long-term debt/capital leases4,199169.97
Other current liabilities, total530457565
Total current liabilities6,8632,6203,024
Total long term debt1044,3623,818
Total debt4,3044,3783,828
Deferred income tax255351267
Minority interest000
Other liabilities, total222223
Total liabilities7,2447,3557,131
SHAREHOLDERS EQUITY
Common stock0.050.050.05
Additional paid-in capital14,09613,93214,024
Retained earnings (accumulated deficit)11,6719,0346,987
Treasury stock - common(109)(28)(58)
Unrealized gain (loss)------
Other equity, total137(291)(924)
Total equity25,79522,64720,029
Total liabilities & shareholders' equity33,03930,00227,160
Total common shares outstanding5,9245,9205,918
Treasury shares - common primary issue9.612.404.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.